A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Phase 3
300
about 6.6 years
12–17
15 sites in CA, DE, GA +6
What this study is about
Researchers are testing tirzepatide, a medication, to see how it affects weight and heart health in adolescents with obesity and related conditions. The trial will last about 76 weeks and may include up to 23 visits.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo
- 2.Take Tirzepatide
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
tirzepatide
injection (Injection)
Primary: Percent Change from Baseline in Body Mass Index (BMI)
Secondary: Change from Baseline in Diastolic Blood Pressure (DBP), Change from Baseline in Hemoglobin A1c (HbA1c), Change from Baseline in Peripheral Apnea-Hypopnea Index (pAHI), Change from Baseline in Systolic Blood Pressure (SBP), Change from Baseline in Waist Circumference, Percent Change from Baseline in Body Weight, Percent Change from Baseline in Total Body Fat Mass as Determined by Dual energy X-ray Absorptiometry (DXA), Percent Change from Baseline in Triglycerides
Endocrinology